Titre : Masoprocol

Masoprocol : Questions médicales fréquentes

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment le masoprocol est-il diagnostiqué ?

Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions.
Masoprocol Diagnostic médical
#2

Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?

Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité.
Essais cliniques Évaluation des symptômes

Symptômes 2

#1

Quels symptômes le masoprocol peut-il traiter ?

Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés.
Inflammation Cancer de la peau
#2

Le masoprocol provoque-t-il des effets secondaires ?

Oui, des effets secondaires comme des irritations cutanées peuvent survenir.
Effets secondaires Irritation cutanée

Prévention 2

#1

Le masoprocol peut-il prévenir des maladies ?

Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes.
Prévention des maladies Traitement
#2

Quelles mesures préventives sont recommandées avec le masoprocol ?

Éviter l'exposition excessive au soleil et suivre les conseils médicaux.
Prévention Exposition au soleil

Traitements 2

#1

Dans quel type de traitement le masoprocol est-il utilisé ?

Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés.
Traitement topique Lésions cutanées
#2

Comment le masoprocol est-il administré ?

Il est généralement appliqué localement sous forme de crème ou de gel.
Administration locale Crème

Complications 2

#1

Quelles complications peuvent survenir avec le masoprocol ?

Des complications comme des infections cutanées peuvent survenir en cas d'irritation.
Complications Infections cutanées
#2

Le masoprocol peut-il interagir avec d'autres médicaments ?

Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin.
Interactions médicamenteuses Consultation médicale

Facteurs de risque 2

#1

Qui est à risque d'effets secondaires du masoprocol ?

Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque.
Facteurs de risque Allergies cutanées
#2

Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?

Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation.
Immunodépression Surveillance médicale
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Masoprocol : Questions médicales les plus fréquentes", "headline": "Masoprocol : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Masoprocol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-01", "dateModified": "2025-03-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Masoprocol" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Catéchols", "url": "https://questionsmedicales.fr/mesh/D002396", "about": { "@type": "MedicalCondition", "name": "Catéchols", "code": { "@type": "MedicalCode", "code": "D002396", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.455.426.559.389.657.166" } } }, "about": { "@type": "MedicalCondition", "name": "Masoprocol", "alternateName": "Masoprocol", "code": { "@type": "MedicalCode", "code": "D009637", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mohammed Baqur S Al-Shuhaib", "url": "https://questionsmedicales.fr/author/Mohammed%20Baqur%20S%20Al-Shuhaib", "affiliation": { "@type": "Organization", "name": "Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq." } }, { "@type": "Person", "name": "Sarfaraz Alam", "url": "https://questionsmedicales.fr/author/Sarfaraz%20Alam", "affiliation": { "@type": "Organization", "name": "Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland." } }, { "@type": "Person", "name": "Salman Ali Khan", "url": "https://questionsmedicales.fr/author/Salman%20Ali%20Khan", "affiliation": { "@type": "Organization", "name": "Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan." } }, { "@type": "Person", "name": "Hayder O Hashim", "url": "https://questionsmedicales.fr/author/Hayder%20O%20Hashim", "affiliation": { "@type": "Organization", "name": "Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq." } }, { "@type": "Person", "name": "Daniel H Obayes", "url": "https://questionsmedicales.fr/author/Daniel%20H%20Obayes", "affiliation": { "@type": "Organization", "name": "College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The distinct ripening processes in the reproductive and non-reproductive parts of the fig syconium are driven by ABA.", "datePublished": "2019-01-01", "url": "https://questionsmedicales.fr/article/30239815", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/jxb/ery333" } }, { "@type": "ScholarlyArticle", "name": "Interactions between Inhibitors and 5-Lipoxygenase: Insights from Gaussian Accelerated Molecular Dynamics and Markov State Models.", "datePublished": "2024-07-30", "url": "https://questionsmedicales.fr/article/39125865", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms25158295" } }, { "@type": "ScholarlyArticle", "name": "Masoprocol: a promising candidate for targeting insulin resistance by inhibiting resistin with optimal druglikeness Potentials: an", "datePublished": "2023-09-06", "url": "https://questionsmedicales.fr/article/37671847", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/07391102.2023.2254842" } }, { "@type": "ScholarlyArticle", "name": "Nordihydroguaiaretic Acid (NDGA) Inhibits CsgA Polymerization, Bacterial Amyloid Biogenesis, and Biofilm Formation.", "datePublished": "2023-08-09", "url": "https://questionsmedicales.fr/article/37195016", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cbic.202300266" } }, { "@type": "ScholarlyArticle", "name": "Quantitative proteomic analysis of tomato fruit ripening behavior in response to exogenous abscisic acid.", "datePublished": "2023-07-21", "url": "https://questionsmedicales.fr/article/37421609", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jsfa.12838" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés chimiques organiques", "item": "https://questionsmedicales.fr/mesh/D009930" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures", "item": "https://questionsmedicales.fr/mesh/D006838" }, { "@type": "ListItem", "position": 4, "name": "Hydrocarbures cycliques", "item": "https://questionsmedicales.fr/mesh/D006844" }, { "@type": "ListItem", "position": 5, "name": "Hydrocarbures aromatiques", "item": "https://questionsmedicales.fr/mesh/D006841" }, { "@type": "ListItem", "position": 6, "name": "Dérivés du benzène", "item": "https://questionsmedicales.fr/mesh/D001555" }, { "@type": "ListItem", "position": 7, "name": "Phénols", "item": "https://questionsmedicales.fr/mesh/D010636" }, { "@type": "ListItem", "position": 8, "name": "Catéchols", "item": "https://questionsmedicales.fr/mesh/D002396" }, { "@type": "ListItem", "position": 9, "name": "Masoprocol", "item": "https://questionsmedicales.fr/mesh/D009637" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Masoprocol - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Masoprocol", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-02", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Masoprocol", "description": "Comment le masoprocol est-il diagnostiqué ?\nQuels tests sont utilisés pour évaluer l'efficacité du masoprocol ?", "url": "https://questionsmedicales.fr/mesh/D009637#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Masoprocol", "description": "Quels symptômes le masoprocol peut-il traiter ?\nLe masoprocol provoque-t-il des effets secondaires ?", "url": "https://questionsmedicales.fr/mesh/D009637#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Masoprocol", "description": "Le masoprocol peut-il prévenir des maladies ?\nQuelles mesures préventives sont recommandées avec le masoprocol ?", "url": "https://questionsmedicales.fr/mesh/D009637#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Masoprocol", "description": "Dans quel type de traitement le masoprocol est-il utilisé ?\nComment le masoprocol est-il administré ?", "url": "https://questionsmedicales.fr/mesh/D009637#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Masoprocol", "description": "Quelles complications peuvent survenir avec le masoprocol ?\nLe masoprocol peut-il interagir avec d'autres médicaments ?", "url": "https://questionsmedicales.fr/mesh/D009637#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Masoprocol", "description": "Qui est à risque d'effets secondaires du masoprocol ?\nY a-t-il des groupes spécifiques à surveiller avec le masoprocol ?", "url": "https://questionsmedicales.fr/mesh/D009637#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le masoprocol est-il diagnostiqué ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité." } }, { "@type": "Question", "name": "Quels symptômes le masoprocol peut-il traiter ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés." } }, { "@type": "Question", "name": "Le masoprocol provoque-t-il des effets secondaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des irritations cutanées peuvent survenir." } }, { "@type": "Question", "name": "Le masoprocol peut-il prévenir des maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes." } }, { "@type": "Question", "name": "Quelles mesures préventives sont recommandées avec le masoprocol ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Éviter l'exposition excessive au soleil et suivre les conseils médicaux." } }, { "@type": "Question", "name": "Dans quel type de traitement le masoprocol est-il utilisé ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés." } }, { "@type": "Question", "name": "Comment le masoprocol est-il administré ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement appliqué localement sous forme de crème ou de gel." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le masoprocol ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des infections cutanées peuvent survenir en cas d'irritation." } }, { "@type": "Question", "name": "Le masoprocol peut-il interagir avec d'autres médicaments ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires du masoprocol ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque." } }, { "@type": "Question", "name": "Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 26/03/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Mohammed Baqur S Al-Shuhaib

1 publication dans cette catégorie

Affiliations :
  • Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq.
Publications dans "Masoprocol" :

Sarfaraz Alam

1 publication dans cette catégorie

Affiliations :
  • Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Publications dans "Masoprocol" :

Salman Ali Khan

1 publication dans cette catégorie

Affiliations :
  • Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Publications dans "Masoprocol" :

Hayder O Hashim

1 publication dans cette catégorie

Affiliations :
  • Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq.
Publications dans "Masoprocol" :

Daniel H Obayes

1 publication dans cette catégorie

Affiliations :
  • College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :

Jafar M B Al-Shuhaib

1 publication dans cette catégorie

Affiliations :
  • College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :

Sources (21 au total)

Interactions between Inhibitors and 5-Lipoxygenase: Insights from Gaussian Accelerated Molecular Dynamics and Markov State Models.

Inflammation is a protective stress response triggered by external stimuli, with 5-lipoxygenase (5LOX) playing a pivotal role as a potent mediator of the leukotriene (Lts) inflammatory pathway. Nordih...

Quantitative proteomic analysis of tomato fruit ripening behavior in response to exogenous abscisic acid.

To determine how abscisic acid (ABA) affects tomato fruit ripening at the protein level, mature green cherry tomato fruit were treated with ABA, nordihydroguaiaretic acid (NDGA) or sterile water (cont... Postharvest tomato fruit underwent faster color transformation and ripening than the CK when treated with ABA. In total, 6310 proteins were identified among the CK and treatment groups, of which 5359 ... ABA affects tomato fruit ripening at the protein level to some extent. The results of this study provided comprehensive insights and data for further research on the regulatory mechanism of ABA in tom...

NDGA enhances the physicochemical and anti-biodegradation performance of dentin collagen.

Collagen fibrils from carious dentin matrix are prone to enzymatic degradation. This study investigates the feasibility and mechanism of nordihydroguaiaretic acid (NDGA), as a collagen crosslinker, to... The physicochemical properties of the crosslinked dentin matrix were characterized by swelling ratio, ninhydrin assay, Fourier Transform Infrared spectroscopy, and atomic force microscopy. The collage... NDGA crosslinked dentin matrix without destroying the integrity of collagen. Mechanistically, NDGA formed bisquinone bond between two adjacent o-quinone groups, resulting in NDGA polymeric matrix in w... NDGA, as a biocompatible collagen crosslinker, improves the mechanical properties and biodegradation resistance of demineralized dentin matrix....

Nordihydroguaiaretic acid inhibits glyoxalase I, and causes the accumulation of methylglyoxal followed by cell-growth inhibition.

Methylglyoxal (MGO) is a known toxic byproduct of glycolysis, with MGO-induced cytotoxicity believed to contribute to the pathogenesis of several diseases. Glyoxalase I (GLO1) is a key enzyme for elim... The inhibitory characteristics of NDGA were determined spectrophotometrically with recombinant GLO1. NDGA-induced growth-inhibition and accumulation of MGO-derived advanced glycation end products (AGE... NDGA showed significant inhibition of GLO1 enzymatic activity in a dose-dependent manner. Its K... NDGA was found to be a novel and potent inhibitor of GLO1. The co-addition of NDGA with MGO to the cells resulted in increased intracellular MGO accumulation followed by enhanced cell-growth inhibitio...

New insights into the antiviral activity of nordihydroguaiaretic acid: Inhibition of dengue virus serotype 1 replication.

Dengue virus (DENV) is considered one of the most important pathogens in the world causing 390 million infections each year. Currently, the development of vaccines against DENV presents some shortcomi... We evaluated the in vitro virucidal and antiviral activity of NDGA on DENV serotype 1 (DENV1), including the study of its mechanism of action, to provide more evidence on its antiviral activity.... The viability of viral particles was quantified by the plaque-forming unit reduction method. NDGA effects on DENV1 genome and viral proteins were evaluated by qPCR and immunofluorescence, respectively... NDGA showed in vitro virucidal and antiviral activity against DENV1. The antiviral effect would be effective within the first 2 h after viral internalization, when the uncoating process takes place. I... The present work contributes to the knowledge of NDGA activity on DENV. We describe its activity on DENV1, a serotype different to those that have been already reported. Moreover, we provide evidence ...